I hold a position in this company. The generic pipeline will be fully taken advantage of by LCI. They will enjoy greater margins as they have a license to import opiates which should grant them an edge over there competition. As patents expire with the other major drug companies; LCI becomes more porfitable and likely attractive for acquisition by one of the majors needing more in its pipeline. There should be multiple buy recommendations on this stock. Just another example of how analysts miss the good ones at the right price for strong buy recommendations. LCI at these levels truely is a bargin. It's time to buy more...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.